147 related articles for article (PubMed ID: 35993018)
21. NCAPG as a Novel Prognostic Biomarker in Glioma.
Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
Front Oncol; 2022; 12():831438. PubMed ID: 35280743
[TBL] [Abstract][Full Text] [Related]
22. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
23. Identification of VASH1 as a Potential Prognostic Biomarker of Lower-Grade Glioma by Quantitative Proteomics and Experimental Verification.
Aili Y; Maimaitiming N; Maimaiti A; Liu W; Qin H; Ji W; Mahemuti Y; Wang Y; Wang Z
J Oncol; 2022; 2022():2621969. PubMed ID: 36504559
[TBL] [Abstract][Full Text] [Related]
24. A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Bai YH; Zhan YB; Yu B; Wang WW; Wang L; Zhou JQ; Chen RK; Zhang FJ; Zhao XW; Duan WC; Wang YM; Liu J; Bao JJ; Zhang ZY; Liu XZ
Cell Physiol Biochem; 2018; 48(4):1755-1770. PubMed ID: 30078018
[TBL] [Abstract][Full Text] [Related]
25.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
26. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
27. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
28. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
29. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
30. IGFBP5, as a Prognostic Indicator Promotes Tumor Progression and Correlates with Immune Microenvironment in Glioma.
Lin J; Huang G; Zeng Q; Zhang R; Lin Y; Li Y; Huang B; Pan H
J Cancer; 2024; 15(1):232-250. PubMed ID: 38164271
[No Abstract] [Full Text] [Related]
31. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
Li J; Wang J; Ding Y; Zhao J; Wang W
BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
[TBL] [Abstract][Full Text] [Related]
32. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
33. RGS16 promotes glioma progression and serves as a prognostic factor.
Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
[TBL] [Abstract][Full Text] [Related]
34. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
35. DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas.
Chang X; Pan J; Zhao R; Yan T; Wang X; Guo C; Yang Y; Wang G
Front Immunol; 2022; 13():917014. PubMed ID: 35812432
[TBL] [Abstract][Full Text] [Related]
36. Predictive significance of PRR11 in prognosis and immune infiltration of glioma patients.
Han W; Chen L
Mol Carcinog; 2023 Jul; 62(7):975-990. PubMed ID: 37036189
[TBL] [Abstract][Full Text] [Related]
37. CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.
Xu Z; Xu H; Chen X; Huang X; Tian J; Zhao J; Liu B; Shi F; Wu J; Pu J
Onco Targets Ther; 2023; 16():819-837. PubMed ID: 37873495
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Prognostic Analysis of Immune Implication Value and Oxidative Stress Significance of NECAP2 in Low-Grade Glioma.
Lu Z; Chen Y; Chen S; Zhu X; Wang C; Wang Z; Yao Q
Oxid Med Cell Longev; 2022; 2022():1494520. PubMed ID: 36531205
[TBL] [Abstract][Full Text] [Related]
39. Tumor Purity as an Underlying Key Factor in Glioma.
Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A
Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819
[No Abstract] [Full Text] [Related]
40. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.
Liu H; Weng J
Gene; 2022 May; 822():146325. PubMed ID: 35183683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]